Limited Competition: Pregnancy as a Window to Future Cardiovascular Health: Adverse Pregnancy Outcomes as Predictors of Increased Risk Factors for Cardiovascular Disease (U10)

The summary for the Limited Competition: Pregnancy as a Window to Future Cardiovascular Health: Adverse Pregnancy Outcomes as Predictors of Increased Risk Factors for Cardiovascular Disease (U10) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Limited Competition: Pregnancy as a Window to Future Cardiovascular Health: Adverse Pregnancy Outcomes as Predictors of Increased Risk Factors for Cardiovascular Disease (U10): This Limited Competition Funding Opportunity Announcement (FOA) encourages applications from the current Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-be (NuMoM2b) clinical research sites and Data Coordinating and Analysis Center (DCAC) to propose a prospective follow-up study of the existing NuMoM2b cohort to examine the cardiovascular (CV) risk profile of women with a history of preeclampsia and other adverse pregnancy outcomes (APOs) at approximately two years postpartum.

Federal Grant Title:	Limited Competition: Pregnancy as a Window to Future Cardiovascular Health: Adverse Pregnancy Outcomes as Predictors of Increased Risk Factors for Cardiovascular Disease (U10)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-HL-13-014
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.233
CFDA Descriptions:	National Center on Sleep Disorders Research
Current Application Deadline:	Oct 31, 2012
Original Application Deadline:	Oct 30, 2012
Posted Date:	Aug 10, 2012
Creation Date:	Oct 30, 2012
Archive Date:	Nov 30, 2012
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Only those institutions in the NuMoM2b parent study funded by the Eunice Kennedy Shriver NICHD at the date of issuance of this FOA are eligible to apply.
Grant Announcement Contact: NIH OER Webmaster [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]]
Similar Government Grants: • Interventions to Reduce Sleep Health Disparities (R01 - Clinical Trials Optional); • Cell and Gene Therapies for HIV Cure: Developing a Pipeline (P01 Clinical Trial Not Allowe...; • NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (...; • NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (...; • Predoctoral Training in Advanced Data Analytics for Behavioral and Social Sciences Researc...; • Ancillary Studies in Clinical Trials (R01); • Opportunity PA-08-021; • Research Demonstration and Dissemination Grants (R18)
More Grants from the National Institutes of Health: • The NCI Worta McCaskill-Stevens Career Development Award for Community Oncology and Preven...; • Interventions to Reduce Sleep Health Disparities (R01 - Clinical Trials Optional); • Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Tri...; • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...